Cholelithiasis
What the FDA labels record as adverse events, each one tied back to the evidence it came from.
What is Cholelithiasis?
Gallstones, listed in Section 5 of every approved GLP-1 label.
Wegovy reports 1.6% against 0.7% on placebo; Saxenda 2.2% against 0.8%. The He et al. 2022 meta-analysis pooled the class risk of cholelithiasis at RR 1.27 (95% CI 1.10–1.47), and of gallbladder or biliary disease overall at RR 1.37 (1.23–1.52). Rapid weight loss of any cause raises the risk, but in Saxenda's trials acute gallbladder disease stayed more common on the drug even after accounting for the weight lost.
Related reading: GLP-1 Pancreatitis and Gallbladder Risk: What the Labels Counted
GLP Watchdog writes these definitions from FDA labels and peer-reviewed PubMed literature.
Where Cholelithiasis comes up on this site
Drug pages
Other terms under Side effects
Where the evidence lives
- The full GLP-1 glossary (150 terms, 8 categories)
- Research articles — written from primary sources
- Tools and calculators
- Compare GLP-1 telehealth providers